The current stock price of INMD is 14.44 USD. In the past month the price decreased by -0.41%. In the past year, price decreased by -9.18%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.09 | 207.82B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.1 | 144.75B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B |
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The firm have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
INMODE LTD
Tavor Building, Sha'ar Yokneam, Pob 533
Yokneam 2069200 IL
CEO: Moshe Mizrahy
Employees: 599
Phone: 97249097470
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The firm have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
The current stock price of INMD is 14.44 USD. The price increased by 1.26% in the last trading session.
INMD does not pay a dividend.
INMD has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
14 analysts have analysed INMD and the average price target is 16.93 USD. This implies a price increase of 17.26% is expected in the next year compared to the current price of 14.44.
The Revenue of INMODE LTD (INMD) is expected to decline by -8.35% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
INMODE LTD (INMD) currently has 599 employees.
ChartMill assigns a technical rating of 1 / 10 to INMD. When comparing the yearly performance of all stocks, INMD is a bad performer in the overall market: 78.31% of all stocks are doing better.
ChartMill assigns a fundamental rating of 7 / 10 to INMD. INMD gets an excellent profitability rating and is at the same time showing great financial health properties.
Over the last trailing twelve months INMD reported a non-GAAP Earnings per Share(EPS) of 1.58. The EPS decreased by -23.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.1% | ||
| ROA | 20.39% | ||
| ROE | 22.93% | ||
| Debt/Equity | 0 |
14 analysts have analysed INMD and the average price target is 16.93 USD. This implies a price increase of 17.26% is expected in the next year compared to the current price of 14.44.
For the next year, analysts expect an EPS growth of -9.69% and a revenue growth -8.35% for INMD